We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Body Fat Sensor Slows Heart Disease

By Biotechdaily staff writers
Posted on 22 Oct 2003
New research has disclosed that a cellular fat sensor in the body slows the development of lesions that could lead to heart disease and suggests this pathway could be used to develop drugs for heart disease. More...
The findings were reported in the October 17, 2003, issue of Science.

Investigators uncovered a regulatory molecule called PPAR-delta (peroxisome proliferator-activated receptor), which plays an important role in the body's inflammatory response to the beginning phase of atherosclerosis. The PPAR-delta switch cuts heart disease in half by disrupting a cellular signal that controls the inflammatory response. Thus, activation of PPAR-delta reduces inflammation and discourages the growth of atherosclerotic plaques.

"The lesions that cause atherosclerosis are very complex and are aggravated,” said Ronald Evans, chair in molecular and developmental biology at the Salk Institute (La Jolla, CA, USA), who along with colleagues conducted the study. "We believe that PPAR-delta normally acts as a molecular soldier to guard against inflammation and disease. Unfortunately, these good effects are compromised by high-fat diets, poor exercise, infections, and stress.”

Dr. Evans suggests that chemicals regulating the activity of PPAR-delta could form the basis of a new drug to reduce atherosclerosis and therefore be a possible therapy for heart disease.




Related Links:
Salk Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.